How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/atelectasis-due-to-mucous-obstruction.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Atelectasis due to Mucous Obstruction — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Atelectasis due to Mucous Obstruction (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Atelectasis due to Mucous Obstruction, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cysteine Hydrochloride	CYSTEINE	Exela Pharma	Vitamin C [EPC]	Cystine/glutamate transporter	1986-01-01
Acetadote	Acetylcysteine	Bristol-Myers Squibb	Antidote	Glutathione levels; reactive metabolite of acetaminophen	1963-01-01
Acetadote	Acetadote	University of Texas Southwestern Medical Center		Cystine/glutamate transporter, Cytochrome c, Glutathione synthetase
Acetylcystein	Acetylcystein	University Hospital, Strasbourg, France		Cystine/glutamate transporter, Cytochrome c, Glutathione synthetase
L-cysteine	L-cysteine	Louisiana State University Health Sciences Center Shreveport	Amino acid derivative	Cystine/glutamate transporter

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Bristol-Myers Squibb · 1 drug in Atelectasis due to Mucous Obstruction
Exela Pharma · 1 drug in Atelectasis due to Mucous Obstruction
Louisiana State University Health Sciences Center Shreveport · 1 drug in Atelectasis due to Mucous Obstruction
University Hospital, Strasbourg, France · 1 drug in Atelectasis due to Mucous Obstruction
University of Texas Southwestern Medical Center · 1 drug in Atelectasis due to Mucous Obstruction

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Atelectasis due to Mucous Obstruction:

Cite this brief

Drug Landscape (2026). Atelectasis due to Mucous Obstruction — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/atelectasis-due-to-mucous-obstruction. Accessed 2026-06-10.

Atelectasis due to Mucous Obstruction full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing